Monday, April 16, 2012

Daiichi Sankyo launches RANMARK (denosumab)

Ranmark was approved by the the Japan Regulators, early this year in January. Ranmark has been inlicensed from Amgen and is approved for the treatment of bone complications / metastasis due to Multiple Myeloma/solid tumors